Cipla Limited – FDA 483, Feb 17, 2023
An FDA inspection of Cipla Limited in Pithampur, India, revealed significant deficiencies across multiple systems, including failures in aseptic processing, environmental monitoring, data integrity, and quality control. The firm failed to thoroughly investigate discrepancies, maintain sterile conditions, control computer systems, and adequately handle numerous patient complaints and field alert reports. These issues indicate a systemic lack of adherence to cGMP regulations for both sterile and non-sterile drug manufacturing.
ID · 0c4d85ed-d21a-4440-8835-7e2f111667e9
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.